An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

NCT01008696 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Reflux Esophagitis

Interventions

DRUG: Rabeprazole
DRUG: Lansoprazole

Sponsor

Janssen Korea, Ltd., Korea